|Place of Origin:||China manufactuer|
|Minimum Order Quantity:||10g|
|Packaging Details:||Special disguised packaging or as your demand|
|Delivery Time:||within 12hours after payment|
|Payment Terms:||T/T, ,|
|Supply Ability:||plent of stock|
|Product Name:||Raloxifene Hydrochloride||CAS:||82640-04-8|
|Assay:||99% Min.||Export Markets:||Global|
|Quality Standards:||USP28||Express:||EMS, DHL, FedEx, Etc(door-to-door)|
steroid raw powder,
medicine raw material
Raloxifene hydrochlorideis an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4SHCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale yellow solid that is very slightly soluble in water.
2. Quick details:
Product name: Raloxifene hydrochloride
CAS : 82640-04-8
Molecular Formula: C28H28ClNO4S
Molecular Weight: 473.58328
Melting point: 143-147degree centigrade
Boiling Point: 728.2 degree centigrade at 760 mmHg
Flash Point: 394.2 degree centigrade
Water solubility:DMSO: 28 mg/mL, soluble
Appearance: Light yellow solid
Indications: This product is mainly used to prevent postmenopausal osteoporosis
Usage of Raloxifene Hydrochloride : Used for the prevention and treatment of postmenopausal osteoporosis, can significantly reduce the incidence of vertebral fractures.
3. Additional Info:
Delivery Time:Within 24 Hours After Payment
Shipping:Express Courier(EMS, DHL, UPS, TNT, FedEx)
Packing:Disguised Package or as Required
Storage: Stored in cool and dry place, keep away from strong light /heat.
Shelf Life: 2 years when properly stored.
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.
5. Function of Cyproterone:
|Test items||Specification||Test results|
|It meets the requirements of the test for choride||Comply|
Soluble in 10% sodium hydroxide solution, slightly soluble
|Related substances||Rrt=0.74 impurity||≤0.20%||Comply|
|Other single impurity||≤0.10%||0.07%|
|Loss on drying||≤0.5%||0.10%|
|Residue on ignition||≤0.1%||Comply|
Preserve in well-closed containers and protected from light.
|Conclusion||Complies with usp32 standard|
Contact Person: Alex